ß2-Adrenoreceptor Agonists, Montelukast, and Parkinson Disease Risk.
Ann Neurol
; 93(5): 1023-1028, 2023 05.
Article
en En
| MEDLINE
| ID: mdl-36897287
ABSTRACT
OBJECTIVE:
This study was undertaken to examine the association between montelukast use, ß2-adrenoreceptor (ß2AR) agonist use, and later Parkinson disease (PD).METHODS:
We ascertained use of ß2AR agonists (430,885 individuals) and montelukast (23,315 individuals) from July 1, 2005 to June 30, 2007, and followed 5,186,886 PD-free individuals from July 1, 2007 to December 31, 2013 for incident PD diagnosis. We estimated hazard ratios and 95% confidence intervals using Cox regressions.RESULTS:
We observed 16,383 PD cases during on average 6.1 years of follow-up. Overall, use of ß2AR agonists and montelukast were not related to PD incidence. A 38% lower PD incidence was noted among high-dose montelukast users when restricted to PD registered as the primary diagnosis.INTERPRETATION:
Overall, our data do not support inverse associations between ß2AR agonists, montelukast, and PD. The prospect of lower PD incidence with high-dose montelukast exposure warrants further investigation, especially with adjustment for high-quality data on smoking. ANN NEUROL 2023;931023-1028.
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Enfermedad de Parkinson
/
Quinolinas
Tipo de estudio:
Etiology_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Ann Neurol
Año:
2023
Tipo del documento:
Article
País de afiliación:
Suecia